Inimex Pharmaceuticals (Canada) developer of medicines that use selective modulation of the innate immune response, closed a $22M Series B financing. Participants include Morningside Venture Investments, Astellas Venture Management, Advantage Life Science Fund, BC Advantage Funds, BDC Capital, British Columbia Discovery Fund, Canadian Medical Discovery Fund and Working Opportunity Fund.